Non-Criteria Obstetric Antiphospholipid Syndrome: How Different Is from Sidney Criteria? A Single-Center Study
Authors:
- Víctor M. Martínez-TaboadaVMVíctor M. Martínez-Taboada
- Pedro Blanco-OlavarriPBPedro Blanco-Olavarri
- Sara Del Barrio-LongarelaSBSara Del Barrio-Longarela
- Leyre Riancho-ZarrabeitiaLRLeyre Riancho-Zarrabeitia
- Ana MerinoAMAna Merino
- Alejandra Comins-BooACAlejandra Comins-Boo
- Marcos López-HoyosMarcos López-Hoyos
- José L. HernándezJosé L. Hernández
Open Access
- 15 November 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2938
Abstract
This study aims to compare the demographic characteristics, clinical features, serology, and fetal–maternal outcomes between women with obstetric antiphospholipid syndrome (APS) and those with non-criteria (NC)-APS and seronegative (SN)-APS. Two-hundred and sixty-three women with APS obstetric morbidity ever pregnant were included. Of those, 66 met the APS classification criteria, 140 were NC-APS, and 57 were SN-APS. Patients with other autoimmune diseases were excluded. Adverse pregnancy outcomes (APO) included early pregnancy loss, fetal death, preeclampsia, abruptio placentae, and preterm birth. The mean age of the study group was 33.6 ± 5.3 years, and patients were followed up for 129.5 ± 81.9 months. In the NC-APS group, 31 (22.1%) did not fulfill clinical and serological criteria (Subgroup A), 49 (35%) did meet clinical but not serologic criteria (Subgroup B), and 60 (42.9%) fulfilled the serologic criteria but not the clinical ones (Subgroup C). The cardiovascular risk burden was higher in the APS group, due to a higher proportion of smoking. Patients with criteria APS received more intensive treatment than patients in the other study groups. The addition of standard of care (SoC) treatment significantly improved live birth and decreased APO in all groups. Significant clinical differences were observed between the study groups. However, when treated with SoC, fetal–maternal outcomes were similar, with a significant improvement in live births and a decrease in APO. Risk stratification in patients with obstetric morbidity associated with APS can help individualize their treatment.Keywords
This publication has 64 references indexed in Scilit:
- Does combined prednisolone and low molecular weight heparin have a role in unexplained implantation failure?Archives of Gynecology and Obstetrics, 2013
- Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective StudyThe Journal of Rheumatology, 2013
- Diagnosis of antiphospholipid syndrome in routine clinical practiceLupus, 2012
- Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levelsJournal of Reproductive Immunology, 2012
- Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS‘)Annals of the Rheumatic Diseases, 2012
- Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancyJournal of Thrombosis and Haemostasis, 2010
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the Randomized, Controlled HepASA TrialThe Journal of Rheumatology, 2009
- ORIGINAL ARTICLE: Occasional Antiphospholipid Antibody Positive Patients with Recurrent Pregnancy Loss Also Merit Aspirin Therapy: A Retrospective Cohort‐Control StudyAmerican Journal of Reproductive Immunology, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006